How Fast Does Basal Cell Carcinoma Grow?

Basal cell carcinoma grows slowly compared with most other cancers, averaging roughly 0.7 mm per month along its longest axis according to a meta-analysis of the available clinical data.¹ That pace sounds almost trivial, but it masks real variability depending on the subtype, body site, and how long the tumor goes untreated. The leisurely tempo is also part of the danger: because BCCs rarely hurt and often look unremarkable, people can ignore them for years while the tumor quietly erodes deeper into tissue.

What the Numbers Actually Show

The best overall estimate comes from a systematic review that pooled data from five studies measuring BCC dimensions over time. The mean growth rate along the longer axis was about 0.71 mm per month, with a standard error of 0.22 mm, reflecting moderate spread across the studies.¹ In practical terms, a BCC left alone for a full year would widen by roughly 8 to 9 mm on average. That is less than a centimeter, which helps explain why many patients describe months of watching a small pink spot before seeking care.

A large community-based study added another dimension to the picture. Rather than tracking tumors in real time, researchers compared the size of BCCs at diagnosis to how long ago patients first noticed them. Tumors noticed within the previous two months served as the baseline. Compared with that baseline, lesions that had been present for two to eight months were only about 10% larger on average, but those left for five to ten years had nearly doubled in size.² The relationship was steady and statistically clear. This does not mean every BCC doubles over a decade; some stall for long periods, while others accelerate. But on a population level, longer delays before treatment correlate with larger tumors in a predictable way.

Why the Subtype Matters More Than the Average

Quoting a single growth rate for “BCC” is like quoting a single speed for “fish.” The tumor comes in several histological subtypes, and they behave quite differently. The meta-analysis noted that the growth rate varied depending on the BCC subtype.¹ Broadly, the most common forms break down like this:

Nodular BCC: The classic pearly bump that most people picture. It tends to grow outward as a dome-shaped lump and is generally well-contained. Its growth rate roughly matches the overall average.
Superficial BCC: Often appears as a flat, scaly pink patch, sometimes mistaken for eczema or psoriasis. It spreads along the skin surface more than it digs deep, and tends to be relatively slow even by BCC standards.
Morphoeic (sclerosing) BCC: This is the one that worries dermatologists. It produces a dense, fibrous stroma and grows in thin, finger-like strands that infiltrate surrounding tissue in unpredictable directions.³ It often looks like a flat, pale scar rather than a bump, making it easy to miss. By the time it is diagnosed, the true margins of the tumor may extend well beyond what the eye can see.

The morphoeic subtype is a particular problem precisely because its surface dimensions can understate the real extent of the cancer underneath. It does not necessarily grow faster in the traditional sense of widening rapidly, but it infiltrates tissue in a way that makes complete removal harder. For surgeons, that translates into wider excision margins and a higher rate of positive margins at first surgery. One study evaluating high-risk BCCs found that even with careful intraoperative assessment, positive deep margins occurred in a meaningful fraction of lesions regardless of size.⁴ In other words, the clinical size you can see on the surface is not always a reliable guide to what is happening below.

What Drives BCC Growth at the Cellular Level

Nearly all basal cell carcinomas are powered by a single misfiring signaling pathway called the hedgehog pathway. In healthy skin, this pathway helps regulate cell growth during development and wound repair. In BCC, mutations in genes that control the pathway, most commonly in a gene called PTCH1, leave the growth signal stuck in the “on” position.⁵ The tumor cells keep dividing, but they do so at a modest pace compared with more aggressive cancers.

Part of the reason BCCs stay relatively slow is that their gene expression profile favors programmed cell death alongside proliferation. A gene-expression analysis comparing BCC cells to squamous cell carcinoma cells found that the genes most strongly active in BCC were enriched for pathways promoting apoptosis, the cell’s built-in self-destruct program.⁶ In plain terms, many BCC cells are growing and dying at roughly comparable rates, which keeps the tumor from ballooning the way a lung cancer or melanoma might. This built-in brake is also one reason BCC almost never spreads to distant organs.

The hedgehog pathway discovery has had practical consequences. Drugs like vismodegib block the pathway directly and can shrink advanced BCCs that are too large or too awkwardly placed for surgery.⁷ These drugs are not used for typical small BCCs, where surgery is straightforward, but they offer an option when the tumor has been neglected for years or sits in an area where cutting would mean losing an eye or a large section of the nose.

What Makes Some BCCs Grow Faster

UV radiation is the single biggest environmental driver. Both cumulative lifetime sun exposure and intermittent high-intensity episodes, like bad sunburns, can promote uncontrolled skin-cell replication and push existing BCCs to grow.⁸ The relationship between UV and BCC location is not always straightforward, though. A study of eyelid BCCs found that tumors on the lower eyelid outnumbered those on the upper lid by a factor of 13, even though measured UV exposure was similar on both lids.⁹ The implication is that other factors, possibly tear film reflectivity or how the brow bone shields the upper lid, shape where tumors actually appear, rather than UV dose alone dictating everything.

Immune suppression also accelerates BCC behavior. People who have had organ transplants and take anti-rejection drugs develop skin cancers far more frequently and tend to see more aggressive subtypes. Age plays a role as well, though disentangling age from accumulated sun exposure is tricky. What is clear is that a BCC developing on a 40-year-old’s back and a BCC developing on an 80-year-old’s nose are not necessarily growing at the same rate, even if both are the same histological subtype.

The Danger of “Slow”

The characterization of BCC as slow-growing and rarely dangerous is accurate as a statistical statement, but it can breed complacency. The tumor grows slowly and rarely metastasizes, unlike squamous cell carcinoma, which tends to spread when left untreated.⁶ But “rarely” is not “never,” and slow growth sustained over many years still adds up to serious tissue destruction.

A case report illustrates the extreme end of the spectrum. A 64-year-old man with a 15-year history of untreated facial BCC presented with a massively ulcerated lesion, chronic drainage, progressive vision loss in one eye, difficulty chewing, and roughly 50 pounds of unintentional weight loss. Imaging showed extensive destruction of the temporal bone, zygomatic arch, and mandibular condyle. A chest CT revealed multiple bilateral lung nodules, and biopsy confirmed metastatic BCC.¹⁰ A cancer that started as a curable skin lesion had, through sheer neglect, eaten through bone and seeded the lungs.

A broader study of patients with locally advanced and metastatic BCC found that among 23 patients who developed metastases, the median time from primary BCC diagnosis to metastasis was about 33 months. The initial spread went to regional lymph nodes in the vast majority of cases, with lungs and bones being the most common distant sites for the subset who eventually developed blood-borne metastases.¹¹ These cases are rare in absolute terms, but they underscore a point: the window of easy treatment is wide open early on, and it narrows the longer you wait.

Can a BCC Shrink on Its Own?

Spontaneous regression of BCC has been documented, though it is uncommon enough to qualify as a medical curiosity rather than something you should count on. In one classic study examining 400 randomly selected BCCs under the microscope, evidence of prior spontaneous regression was found in about 6% of tumors. Another 14% showed small, localized areas of active immune-mediated regression, where the body’s immune cells were visibly attacking tumor nests, though these zones were typically tiny.¹² This suggests the immune system does mount a defense against BCCs in some patients, even though it rarely succeeds in eliminating the tumor entirely.

Full spontaneous regression, where the whole tumor disappears without treatment, is documented mainly through individual case reports. One described an 84-year-old patient whose BCC regressed completely, with biopsy showing dense infiltration of immune cells in the tumor remnants.¹³ These events are interesting for what they reveal about the immune response to BCC, but they are far too rare to justify a wait-and-see approach. A BCC that appears to be getting smaller still needs evaluation, because the visible surface can shrink while deeper components continue to invade.

The Role of the Tumor’s Surroundings

Recent research has started looking beyond the tumor cells themselves and into the microenvironment, the surrounding tissue that a BCC lives within. Cancer-associated fibroblasts, cells that normally help with wound healing, get co-opted by tumors to build a supportive scaffold. A single-cell analysis of skin tumors identified a fibroblast subtype found exclusively in BCC that showed traits associated with invasive and destructive behavior, correlating with tumor progression.¹⁴

This is still early-stage research, but it adds nuance to the growth-rate question. Two BCCs that look identical on the surface might grow at different rates depending on the fibroblast population surrounding them. The morphoeic subtype, with its dense fibrous stroma, could represent an extreme case of this fibroblast co-optation, where the tumor’s surrounding tissue actively facilitates infiltrative spread. It also hints at future therapeutic targets: if you could disrupt the supportive fibroblast environment, you might slow a BCC’s progression even without directly killing tumor cells.

Practical Implications for Getting a BCC Checked

Knowing that BCCs grow at roughly 0.7 mm per month does not mean you have a precise countdown clock. Some tumors sit nearly dormant for years; others, particularly aggressive subtypes on UV-exposed sites, expand steadily. What the growth rate data does tell you is that a delay of a few weeks to get a dermatology appointment is not going to transform a small BCC into something dangerous. But a delay of several years absolutely can.

The practical takeaway is that urgency scales with time. If you notice a new pearly bump or a non-healing sore that bleeds and crusts over repeatedly, getting it checked within a few months is reasonable. You do not need to treat it as a same-day emergency the way you might with a rapidly changing mole that raises melanoma concerns. But “it’s probably nothing” combined with five years of avoidance is how manageable lesions become the kind of locally advanced tumors that require complex reconstructive surgery or systemic drug therapy.

Location matters for the calculus as well. BCCs on the nose, around the eyes, and near the ears sit in areas where even a centimeter of growth can compromise important structures. A tumor on the back can grow to considerable size with little functional consequence beyond cosmetics, but the same growth rate on the inner corner of the eye is a different story entirely. Dermatologists classify facial BCCs in certain high-risk zones partly because the consequences of delayed treatment are more severe there, not because the tumor itself necessarily behaves differently.

How BCCs Are Tracked Without Repeated Biopsies

For patients being monitored or treated with topical therapy rather than immediate surgery, clinicians increasingly use non-invasive imaging to assess whether a BCC is growing. Optical coherence tomography, which works somewhat like an ultrasound but uses light instead of sound, can visualize the layers of skin in real time and help identify tumor margins without cutting.¹⁵ Dermoscopy, the handheld magnifying tool dermatologists hold against the skin, also provides useful clues about subtype and growth pattern.

These tools do not replace biopsy for a definitive diagnosis, but they help answer the follow-up question patients often have: “Is it getting bigger?” For superficial BCCs being treated with a topical cream like imiquimod, periodic imaging can confirm the tumor is responding without repeated tissue samples. For morphoeic variants, imaging helps map the true extent of the lesion before surgery, reducing the chance of an incomplete first excision. The slow growth rate of most BCCs makes serial monitoring a viable strategy in select cases, though watchful waiting without any treatment plan is not recommended even for the most indolent-looking lesions.

When Growth Rate Varies From Expectations

Occasionally a BCC grows faster than the textbook average, and understanding why can help set expectations. Recurrent BCCs, tumors that come back after incomplete excision, often grow more aggressively than the original lesion. The surgical disruption may alter the local tissue environment or select for more infiltrative cell populations. Similarly, BCCs arising in previously irradiated skin, such as in patients who had radiation therapy for another cancer years earlier, sometimes behave more aggressively.

On the other end, some BCCs can appear almost static for years. Patients sometimes report a small spot they have watched for a decade with no obvious change, only to have a biopsy confirm it is indeed a BCC. In these cases the tumor may be cycling between slow growth and partial immune-mediated regression, resulting in a net change so subtle that it is invisible to the naked eye. The 6% spontaneous regression rate found on microscopic examination hints that this tug-of-war between immune clearance and tumor growth is more common than clinical observation suggests.

If you have a diagnosed BCC and your dermatologist recommends treatment, the growth rate should not be the deciding factor in whether you agree. Even the slowest-growing BCC will not get better on its own in the vast majority of cases, and treatment at a small size is simpler, cheaper, and leaves a smaller scar than treatment after years of accumulation. The speed at which it grows is mostly relevant for understanding how quickly you need to act, and for most people, the honest answer is: soon, but not frantically.

1
PubMed Central. Growth rate of basal cell carcinoma: a meta-analysis and systematic review
2
Journal of the American Academy of Dermatology. Basal cell carcinoma and squamous cell carcinoma growth rates and determinants of size in community patients
3
PubMed. alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation
4
PubMed Central. Role of Intraoperative Clean Surgical Margin Determined With Lesion Size and Duration to Obtain Apropriate Histological Clean Surgical Margin in High-Risk Basal Cell Carcinoma Patients, According to National Comprehensive Cancer Network Criteria
5
PubMed. Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
6
Indonesian Journal of Cancer. The Differential Gene Expression of Squamous Cell Carcinoma Versus Basal Cell Carcinoma Highlights Oxidative Phosphorylation As A Potential Factor in Metastasis: A Single-Cell Gene Expression Analysis Study
7
PubMed Central. Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond
8
PubMed Central. Ultraviolet Radiation and Basal Cell Carcinoma: An Environmental Perspective
9
PubMed Central. Basal cell carcinoma of the eyelids and solar ultraviolet radiation exposure
10
PubMed Central. Pulmonary Metastases From a Long-Standing Untreated Facial Basal Cell Carcinoma: A Rare Case Report
11
Acta Dermato-Venereologica. Clinical Features and Outcomes of Locally Advanced and Metastatic Basal Cell Carcinoma
12
PubMed. Spontaneous regression in basal cell carcinomas
13
PubMed Central. Basal Cell Carcinoma with Spontaneous Regression: A Case Report and Immunohistochemical Study
14
PubMed. Pan-Cancer Single-Cell Analysis Revealing the Heterogeneity of Cancer-Associated Fibroblasts in Skin Tumors
15
PubMed Central. In Vivo Optical Coherence Tomography for the Detection, Subtyping, and Margin Assessment of Facial Basal Cell Carcinoma: A Comparative Study with Histopathology